Bahrain Mumtalakat Holding Company BSC(c), the country’s sovereign wealth fund, has partnered with SandboxAQ, a leading global company in artificial intelligence and quantum technologies, to
Hemab Therapeutics, a biotechnology company in the clinical stage that focuses on creating new preventative treatments for rare and overlooked bleeding and blood clotting disorders,
SimBioSys, a precision medicine company using artificial intelligence to improve cancer care, announced that its FDA-cleared TumorSight Viz technology was recently featured on ABC News
A new study published in Neurology Clinical Practice, the journal of the American Academy of Neurology, has found that two blood tests using multiple biomarkers
Johnson & Johnson has released new 96-week data from the long-term extension phases of its Phase 3 GRAVITI, GALAXI 2, and GALAXI 3 trials. The
Welcome to your Weekly Dose of Health Tech Innovation!Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.We bring you expert-curated insights,
MiraSol Health, a leading community-based nonprofit provider of compassionate palliative, end-of-life, and grief care services in Beaufort, Jasper, Colleton, and Hampton counties, is excited to
Summit Medical Group has partnered with Sylvan Health to expand access to virtual, evidence-based nutrition care for patients across Tennessee, helping improve chronic disease management
State is pleased to announce the promotion of Brandon Huisman to Vice President of Digital Communications and Operational Strategy. Health Technology Insights: Fractal Earns AWS Generative
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced the appointment of Abraham Bassan and Vasudev
Neurodegenerative diseases are among the biggest health issues we face presently. In Germany, about 1.8 million people are living with dementia, and that number is
Biogen Inc. and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy
